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ABSTRACT 
 
In some human infections including those of blood, skin and respiratory tract, the causative 
bacterial agents tend to overlap, especially Staphylococcus spp. and Streptococcus spp. Such 
overlaps constitute difficulties in the choice of diagnostic tools, antibacterial chemotherapy and 
infection control strategies. To resolve this challenge, we developed a pentaplex PCR assay which 
simultaneously detects sequences for the recognition of bacteria (bacterial 16S rRNA), the genus 
staphylococcus translation elongation factor Tu (tuf), Staphylococcus aureus (spa), mecA-encoded 
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staphylococcal methicillin resistance (mecA) and the S. aureus Panton-Valentine leukocidin (PVL) 
virulence factor (pvl). The new pentaplex PCR assay was validated using standard bacterial strains 
(N=377) including strains from the Network on Antimicrobial Resistance in Staphylococcus aureus 
(NARSA), the National Collection of Type Cultures (NCTC), and the National Collection of Industrial 
and Marine Bacteria (NCIMB). The new pentaplex PCR assay enables inference of bacterial 
presence/absence, differentiates between the genus Staphylococcus spp. and other bacteria, 
separates S. aureus from other Staphylococcus spp., differentiates between methicillin-susceptible 
and methicillin-resistant staphylococci, and detects the S. aureus PVL gene locus. The negative 
predictive value was 100% while the positive predictive value was 100%. Using a 96-well plate, the 
time to result was 2.5 hours against ≥24 hours by bacteriological culture. The new pentaplex PCR 
assay can easily be integrated into routine diagnostic microbiology workflow especially for 
laboratories with slim budgets which are unable to incorporate next generation sequencing at the 
moment.  
 
 
Keywords: Differential diagnosis; pentaplex PCR; MRSA; panton-valentine leukocidin. 
 
1. INTRODUCTION 
 
Recent studies have illuminated the abundance 
and diversity of bacteria in/on different parts of 
the human body [1,2]. As more microbiomic data 
appear, differential diagnostic tools will be 
necessary to identify particular genetic factors 
associated with diseases and their outcomes [3]. 
The first strains of methicillin resistant 
Staphylococcus aureus (MRSA) were reported in 
the United Kingdom hospitals about the same 
time as the introduction of the antibiotic 
methicillin [4,5]. Following the UK reports, MRSA 
clones with diverse genetic backgrounds and 
virulence factors have been reported worldwide 
[6]. Following the establishment of the centrality 
of mecA gene in the mechanism of 
staphylococcal methicillin resistance [7], 
polymerase chain reaction (PCR) detection of 
mecA DNA gained wide acceptance [8].  
 
In 2004, it was observed that some MRSA 
strains were not detected by mecA PCR, rather, 
five primers specific to different staphylococcal 
cassette chromosome mec (SCCmec) right 
extremity sequences, including three new 
sequences and specific to the S. aureus 
chromosomal orfX, a gene of unknown function, 
located to the right of the SCCmec integration 
site, were the most reliable for the identification 
of some MRSA strains [9]. The orfX information 
informed the development of several commercial 
MRSA assays including Xpert MRSA assay 
(Cepheid, California, USA) and BD-GO (Becton-
Dickinson, USA). However, neither orfX nor the 
recently reported hybrids and analogues [10,11] 
reduced the centrality of mecA in staphylococcal 
methicillin resistance.   
 
Whereas mecA gene driving methicillin 
resistance is shared among S. aureus and other 
staphylococci [6,7], Panton-Valentine leukocidin 
(PVL) encoded by lukSF-PV operon and 
staphylococcal protein A (Spa) encoded by the 
spa gene, both of which are associated with skin 
and airways diseases, are unique to S. aureus 
[12,13]. The staphylococci and other bacterial 
species associated with human infections all 
share the tuf gene encoding translation 
elongation factor Tu as well as the 16S rRNA 
gene [14]. 
 
Independently, S. aureus strains expressing Spa, 
PVL, or PBP2a are sources of concern to 
infection control, laboratory diagnosis and anti-
staphylococcal therapy [15]; their convergence 
highlights a higher threat to public health 
microbiology [16]. It has been suggested that the 
application of multiplex PCR for the detection of 
multiple genetic markers within the same sample 
will provide a major contribution to the efficiency, 
logistics and cost-effectiveness of molecular 
diagnostics [17]. In this regard, some previously 
developed MRSA and PVL assays have been 
revisited recently. As Pichon and colleagues 
envisaged that S. aureus harbouring 
mecA(LGA251), a recently identified livestock 
variant of mecA, could be wrongly identified as 
methicillin-susceptible S. aureus (MSSA) in the 
absence of antimicrobial susceptibility testing 
(AST), they modified a triplex real-time PCR 
assay published in 2005 by McDonald and 
colleagues [18] into a quadruplex assay [19]. 
 
There are several reports of simultaneous 
sequencing and clustering of large numbers of 
16S rRNA genes enabled by next generation 
sequencing (NGS) [20]. However, multiplex 
detection of virulence and antibiotic resistance 
 
 
 
 
Okolie and James; JABB, 2(4): 250-259, 2015; Article no.JABB.2015.025 
 
 
 
252 
 
genes is not common at the moment. NGS 
machines and analysis of the associated 
metagenomic sequence data are currently 
possible only by high-budget laboratories [21]. 
PCR-based MRSA and PVL assays do not 
distinguish between staphylococci and other 
bacterial agents of skin and airways disease. To 
provide this necessary advancement, we studied 
a triplex assay for simultaneous detection of S. 
aureus spa, mecA and lukSF-PV [22] and added 
two more DNA targets, namely: Bacterial 16S 
rRNA and staphylococcal tuf, thus arriving at a 
new pentaplex PCR. Sequencing and phenotypic 
tests were used to validate the new assay 
according to current practices.  
 
2. MATERIALS AND METHODS 
 
2.1 Bacterial Strains and Microbiological 
Media Used for This Study 
 
All microbiological media and consumables, 
except otherwise mentioned, were obtained from 
Oxoid (Oxoid, Basingstoke, UK). Bacterial strains 
were obtained from ultra-cold (-80°C) storage, 
sub-cultured in brain heart infusion (BHI) broth 
and plated out on BHI plates and sheep blood 
agar (Oxoid, UK) as reported previously [23]. A 
total of 377 bacterial strains were used for 
evaluation through four panels (2.2.1 – 2.2.4).  
 
Type culture staphylococcal strains (n=50) listed 
in Table 1. They were obtained from the Network 
for Antibiotic Resistance in Staphylococcus 
aureus (NARSA) Strain Repository 
(www.narsa.net), the National Collection of Type 
Cultures (NCTC) and the National Centre for 
Industrial and Marine Bacteria (NCIMB) and used 
to validate the 5 key markers targeted by the new 
assay. Necessary genomic information for the 
reference type cultures were obtained from the 
homepages of the suppliers.  
 
Randomly selected (n=240) from reference 
clinical staphylococcal strains (RSS) previously 
characterized at the Queen’s Medical Centre 
(QMC) Nottingham between August 2003 and 
December 2004. RSS data from QMC identified 
them as S. epidermidis (n=72) of which 45 were 
methicillin resistant (MRSE), and S. aureus 
(n=168) including 92 MRSA. They were 
previously identified phenotypically by coagulase 
as S. aureus and by latex agglutination for 
MRSA, but were not tested for PVL at the time. 
The staphylococci (2.1.1 and 2.1.2) were 
collected and stored by Dr. Richard Spence who 
used them for validation of DNA microarrays [23].   
 
Table 1. Staphylococcal type culture strains 
and their sources 
 
Serial 
no. 
Isolate Species or 
group  
Sourcea 
1 NRS1 S. aureus NARSA
b
 
2 NRS102 S. aureus NARSA 
3 NRS103 S. aureus NARSA 
4 NRS110 S. aureus NARSA 
5 NRS111 S. aureus NARSA 
6 NRS112 S. aureus NARSA 
7 NRS113 S. aureus NARSA 
8 NRS114 S. aureus NARSA 
9 NRS123 S. aureus NARSA 
10 NRS13 S. aureus NARSA 
11 NRS147 S. aureus NARSA 
12 NRS149 S. aureus NARSA 
13 NRS153 S. aureus NARSA 
14 NRS157 S. aureus NARSA 
15 NRS158 S. aureus NARSA 
16 NRS162 S. aureus NARSA 
17 NRS164 S. aureus NARSA 
18 NRS165 S. aureus NARSA 
19 NRS167 S. aureus NARSA 
20 NRS170 S. aureus NARSA 
21 NRS171 S. aureus NARSA 
22 NRS172 S. aureus NARSA 
23 NRS176 S. aureus NARSA 
24 NRS179 S. aureus NARSA 
25 NRS182 S. aureus NARSA 
26 NRS185 S. aureus NARSA 
27 NRS188 S. aureus NARSA 
28 NRS191 S. aureus NARSA 
29 NRS192 S. aureus NARSA 
30 NRS194 S. aureus NARSA 
31 NRS227 S. aureus NARSA 
32 NRS229 S. aureus NARSA 
33 NRS231 S. aureus NARSA 
34 NRS233 S. aureus NARSA 
35 NRS244 S. aureus NARSA 
36 NRS248 S. aureus NARSA 
37 NRS249 S. aureus NARSA 
38 NRS255 S. aureus NARSA 
39 NRS260 S. aureus NARSA 
40 NRS265 S. aureus NARSA 
41 NRS70 S. aureus NARSA 
42 NRS71 S. aureus NARSA 
43 NRS72 S. aureus NARSA 
44 NRS8 S. epidermidis NARSA 
45 NRS9 S. haemolyticus NARSA 
46 NRS69 S. haemolyticus NARSA 
47 NCTC12217 S. lugdunensis NCTCc 
48 NCTC11042 S. haemolyticus NCTC 
49 NCIMB9993 S. epidermidis NCIMBd 
50 NCIMB700787 S. capitis NCIMB 
aGenomic information available at suppliers’ website, 
bNARSA = Network for Antibiotic resistance in 
Staphylococcus aureus, cNCTC = National Collection of Type 
Cultures, d NCIMB = National Collection of Industrial and 
Marine Bacteria 
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Additional CoNS (n=40) donated by researchers 
at the Nottingham University’s Centre for 
Biomolecular Sciences (CBS) who previously 
identified them as S. auricularis (3 strains), S 
capitis (2 strains), S. caprae (2 strains), S. 
chromogenes (1 strain), S. cohnii (2 strains), S. 
epidermidis (2 strains), S. hemolyticus (4 
strains), S. hominis (4 strains), S. intermedius (2 
strains), S. lugdunensis (1 strain), S. 
saprophyticus (3 strains), S. sciuri (4 strains), 
and S. warneri (1 strain). 
 
Non-staphylococcal bacterial strains (n=47) 
previously characterized by CBS microbiology 
research groups including some strains of 
Escherichia coli, Pseudomonas spp., Klebsiella 
spp., Aeromonas spp., Salmonella spp., 
Citrobacter spp., Proteus spp., and Group A 
streptococci (GAS).  
 
2.2 Bio Safety 
 
Safety is emphasised in our laboratory. Given 
that most NARSA isolates are potentially 
hazardous, work on them were carried out in 
enhanced level 2 (BSL2+) suite designated for 
such pathogens. Local bacterial strains were 
handled completely in the general (BSL 2) 
laboratory space where they have been 
circulating prior to this study. 
 
2.3  Preparation of Bacterial Inoculum for 
PCR and Phenotypic Tests 
 
For each bacterial strain used in this study, a 0.5 
McFarland standardised inoculum was prepared 
and used for PCR and for phenotypic tests.   
 
2.4 Extraction of Bacterial DNA for PCR 
 
Extraction of DNA from NARSA isolates grown 
on BHI plates was performed by heating and 
centrifugation as reported previously [24]. Briefly, 
0.5 mL live bacterial suspension was killed 
(95°C, 10 minutes). Following a quick 
centrifugation (13000 RPM, 20 seconds), the 
DNA-rich supernatant was transferred into a 
fresh 0.5 mL Eppendorf tube for PCR in the 
general (BSL 2) laboratory.  
 
DNA extraction was waived for local strains. 
Isolates were applied directly into the PCR from 
BHI broths, blood agar plates, BHI plates and 
from 0.5 McFarland broths. 
2.5 Design of Oligonucleotide Primers 
 
The sequences of the oligonucleotide primers 
used in the new pentaplex PCR assay are 
presented in Table 2. The primers targeting spa, 
pvl and mecA were published originally for a 
triplex real-time PCR assay [22]. The primers 
targeting 16S rRNA and tuf were designed for 
this study. Numerous nucleotide sequences for 
each marker were sourced from the National 
Centre for Biotechnology Information (NCBI)              
and entered into clusta lW suite                                     
at the European Bioinformatics Institute 
(www.ebi.ac.uk/tools/clustalW) for multiple 
alignments which allowed identification of highly 
conserved motifs (HCMs) for hybridization of 
primers targeting bacterial 16S rRNA and 
staphylococcal tuf genes. Primers were located 
manually according to Mount [25]. All primers 
were purchased from Sigma Genosys (Sigma, 
UK).  
 
2.6 Performance and Optimization of New 
Pentaplex PCR  
 
PCR amplification was performed incorporating 
5.0 µL of the template in a 40 µL PCR using 
Eppendorf mastercycler (Eppendorf, Hamburg, 
Germany) following the cycling conditions 
described by Nakagawa et al. [22] with 
modifications. Briefly, an initial single cycle for 5 
minutes at 94°C was followed by 40 cycles 
consisting of 15 seconds at 94°C (denaturation) 
and 5 seconds at 60°C (amplification) with one 
final run of 30 seconds at 72°C (final polymerase 
extension). The reaction was then cooled to 4ºC 
for post-amplification processes. PCR 
optimization followed previously described 
methods [26,27]. The optimized factors driving 
the new pentaplex PCR assay are listed in              
Table 3.  
 
2.7 Gel Resolution and Gel Purification of 
PCR Products 
 
PCR products were resolved using conventional 
Tris-EDTA buffer submarine electrophoresis (200 
V, 1 h) in 2% agarose gel containing Ethidium 
bromide (0.5 g/L) and visualised in UV trans-
illuminator (UVP, UK). PCR products were 
purified from agarose gels using GenElute™ 
(Sigma, UK) according to manufacturer’s 
instructions. 
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Table 2. Sequences of oligonucleotide primers used in the new pentaplex PCR assay 
 
Target  
DNA 
Amplicon 
size (bp) 
Primer 
identity 
Primer sequence 5'→  3' Reference/ 
source
a 
16S 174 16S-1 CTAGTAATCGCGGATCAGCAT This study 
study
c
 16S-2 GATACGGCTACCTTGTTACGACTT 
mecA 155 mecA-1 TGGTATGTGGAAGTTAGATTGGGAT [22] 
mecA-2 CTAATCTCATATGTGTTCCTGTATTGGC 
tuf 143 tuf-1 TACCAGCATTAGTAGTATTCTTAAACAAAGTTG This study 
s tuf-2 TGCTGAACCAGCGATTACAG 
pvl 118 pvl-1 TTACACAGTTAAATATGAAGTGAACTGGA [22] 
pvl-2 AGCAAAAGCAATGCAATTGATG 
spa 101 spa-1 CAGCAAACCATGCAGATGCTA [22] 
spa-2 CGCTAATGATAATCCACCAAATACA 
aThe mecA, pvl, and spa primers were designed by Nakagawa et al. [22] while the two sets of differential primers 
targeting bacterial 16S rRNA and staphylococcal tuf were designed in this study 
 
Table 3. Optimal constituents of the new pentaplex PCR 
 
Factor  Optimal value/concentration 
Primers  0.75 µM 
dNTPs 0.500 mM 
Taq DNA polymerase 5.0 U (NEB) 
Thermopol buffer (pH 8.8 at 25°C)
a
 5 µL amounting to: 20 mM Tris-HCl, 10 mM (NH4)2SO4, 
10 mM KCl, 2 mM MgSO4, 0.1% Triton X-100.  
Time to complete a 50-cycle PCR run 77 minutes 
a 
Our laboratory maintains controlled temperature, approximately 25°C 
 
2.8 Sequencing of PCR Products and 
Sequence Analysis 
 
Sequencing reactions were generated by 
BigDyeTM protocol (Applied Biosystems, USA) 
and analysed on Prism 310 Genetic analyser 
(Abbott Laboratories, USA). Identity of PCR 
products were analysed by BLAST searches on 
the NCBI databases and used to confirm the 
amplified sequences as spa, tuf, 16S rRNA, pvl, 
or mecA. The obtained sequence data were 
combined together to identify the strains as 
MRSA, PVL-positive MRSA (PPMRSA), MSSA, 
PVL-positive MSSA (PPMSSA), methicillin 
susceptible CoNS (MSCoNS), methicillin 
resistant CoNS (MRCoNS), or other bacteria.  
 
2.9 Validation of the New Pentaplex PCR 
Assay Using Conventional 
Phenotypic Tests 
 
Without disclosing their genotypic and 
phenotypic properties, bacterial strains were 
taken from the freezer and tested on the new 
pentaplex PCR assay as RSS001, RSS002, 
RSS007, etc,. The finding of Gram positive cocci 
in clusters was used to characterise 
Staphylococcus spp. Tube coagulase test was 
used to differentiate S. aureus from CoNS. 
Staphylococcus spp. were examined for 
staphylococcal methicillin resistance by oxacillin 
salt agar screen (OSAS) according to Clinical 
and Laboratory Standards Institute (CLSI) 
recommendation [28] with modification of the 
oxacillin content based on a more recent work 
used in the UK to support the real-time PCR 
detection of mecA and mecA(LGA251) in S. aureus 
[19]. Briefly, duplicate Mueller-Hinton agar plates 
supplemented with 4% NaCl and 0.5 mg/L 
oxacillin were incubated in ambient air at 30°C or 
35°C for 24 hours. Plates were examined 
carefully with transmitted light for evidence of 
small colonies (>1 colony) or a light film of 
growth indicating oxacillin resistance. Non-
staphylococcal bacteria were not tested for 
methicillin resistance. Obtained results were 
compared against phenotypic tests used to 
support the new assay as well as the QMC 
phenotypic information held by Dr. Spence. 
 
2.10 Statistical Analysis  
 
Negative predictive value (NPV) and positive 
predictive value (PPV) of the new pentaplex PCR 
assay were analysed according to the Clinical 
and Laboratory Standards Institute (CLSI) 
Guidelines for molecular diagnostics [29].  
 
 
 
 
Okolie and James; JABB, 2(4): 250-259, 2015; Article no.JABB.2015.025 
 
 
 
255 
 
3. RESULTS AND DISCUSSION  
 
Use of bioinformatics tools enabled the selection 
of primer pairs for the amplification of a 174 bp 
region from ubiquitous bacterial 16S rRNA gene 
and a 143 bp region from the translation 
elongation factor Tu (tuf) gene of Staphylococcus 
spp. Those two primer sets were added into the 
previously described triplex assay to scale up to 
the new pentaplex assay thus allowing all the 5 
targets to be amplified simultaneously (Fig. 1). 
 
Testing of 377 bacterial isolates on the new 
assay showed the new assay detected the 
expected genes from all the bacterial strains 
studied. The new assay was able to differentiate 
between Staphylococcus spp. and non-
staphylococcal bacteria. A wide spectrum of S. 
aureus types, including methicillin-susceptible 
and methicillin-resistant strains of diverse 
SCCmec backgrounds previously tested on Dr. 
Richard Spence’s microarray were identified. 
 
As evident in Fig. 2, the pentaplex PCR was able 
to distinguish staphylococci from non-
staphylococcal bacteria such as E. coli, Proteus 
spp., and Group A Streptococcus (GAS). The 
detection of the bacterial 16S rRNA as the only 
marker in the PCR (Fig. 2, Lane 1) clearly 
indicated bacterial presence of non-
staphylococcal background. The pattern of Fig. 2 
Lane 1 was found with GAS, E. coli, Proteus spp. 
and other non-staphylococcal bacteria. This is an 
advantage of the nes assay which is not common 
to most PCR assays reported in literature. 
Numerous PCR assays designed to detect S. 
aureus PVL and MRSA lack the quality of 
showing the presence of eubacteria of non-
staphylococcal background. This is especially 
important in pure cultures. Very few such PCRs 
carry a DNA band for a sequence unique to S. 
aureus such as the staphylococcal 16S rRNA, a 
role well played by the staphylococcal tuf in the 
new pentaplex PCR assay. The detection of the 
broad-range 16S rRNA would be very useful in 
the differential diagnosis of skin and soft-tissue 
infections in which the clinical presentations of 
staphylococcal and streptococcal diseases are 
often similar and tend to overlap. As the tuf 
marker was not detected from non-
staphylococcal bacteria (100% NPV), its 
detection strongly evidenced the presence of a 
member of the genus Staphylococcus, thus 
conferring a double assurance of staphylococcal 
diagnosis. This is essential both for the institution 
of empirical therapy and for the purposes of 
infection control. 
Using the new pentaplex PCR assay, gene 
detection for spa, tuf, 16S rRNA, pvl, and mecA 
which were combined to inform identification of 
MRSA, PVL-positive MRSA (PPMRSA), MSSA, 
PVL-positive MSSA (PPMSSA), methicillin 
susceptible CoNS (MSCoNS), methicillin 
resistant CoNS (MRCoNS), and other bacteria 
corroborated the phenotypic tests used as well 
as the previous QMC data. All (100%) of the 377 
bacteria studied generated the bacterial 16S 
rRNA marker thus yielding a 100% PPV. All other 
markers were generated with very high level 
specificity. No spurious amplification (100% 
NPV) and no expected marker was left 
undetected (100% PPV). All other markers were 
generated with very high level specificity. No 
spurious amplification (100% NPV) and no 
expected marker was left undetected (100% 
PPV). 
 
BLAST data was inadequate in discriminating 
between PCR fragments of 16S rRNA from 
bacterial strains of staphylococcal and non-
staphylococcal background. Using the new 
assay, the staphylococcal tuf showed greater 
discriminatory power than 16S rRNA. This 
attribute of the new assay will be helpful in 
separating clinical isolates of staphylococci 
(positive for tuf) from other bacteria (negative for 
tuf). This finding is supported by previous reports 
[30] and helps to explain the cause of failure of 
tiny 16S rRNA PCR fragments for taxonomical 
work as such tiny PCR fragments of 16SrRNA 
are not discriminatory enough [31].  
 
The new pentaplex PCR assay completes 40 
cycles in 37 minutes. The total time from sample 
preparation to gel documentation, also called the 
turn-around time (TAT), was 4 hours for a 96-well 
plate. This is a very good outcome compared 
with ≥24 hours required to identify staphylococcal 
methicillin resistance when microbiological agar 
is in use. This is especially important in blood 
cultures where the finding of GPC in clusters 
from positive blood cultures has become a public 
health concern.  
 
In addition to the PCR primers listed in Table 2, 
other PCR factors optimized for the new 
pentaplex PCR assay are summarized in Table 
3. Early in the history of PCR, optimization of 
PCR assays used to be so cumbersome that the 
list of factors identified as having influence on 
PCR was never to be complete [32]. 
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Fig. 1. The new pentaplex PCR assay and consituent monoplexes resolved in 2.5% agarose 
Lane 1 is the new pantaplex PCR showing from top to bottom respectively, the bands for: Bacterial 16SrRNA 
(174 bp),mecA (155 bp),staphylococcal tuf (143 bp), pvl(118 bp),and spa (101 bp).Singal target PCRs are: 
spa(Lane 2), pvl (Lane 3), staphylococcal tuf (Lane 4) mecA (Lane 5), bacterial 16S rRna (Lane 6).Controls are: 
Negative PCR control with PCR grade water as template (Lane 7), 100bp DNA marker(Lane 8) 
 
 
 
Fig. 2. Agarose gel (4%) resolution of pentaplex PCR products on various bacterial isolates 
Group A Streptococcus (GAS) showing only the DNA band for bacterial 16SrRNA (Lane 1), PVL-negative MRSA 
S. aureus strain Mu50 showing, from top to bottom, the four DNA bands respectively marking the bacterial 16S 
rRNA, mecA, staphylococcal tuf, and spa (Lane 2), Meticillin Resistant Staphylococcus epidermidis strain NRS8 
showing the markers for bacterial 16S rRNA, mecA and staphylococcal tuf (Lane 3), PVL-positive MSSA S. 
aureus strain NRS158 showing the DNA bands for bacterial 16S rRNA, staphylococcal tuf, pvl, and spa, from top 
to bottom, respectively (Lane 4), No Template DNA (Lane 5), PVL-negative MRSA S. aureus Sanger 252 
showing, from top to bottom, the four DNA bands respectively depicting the bacterial 16S rRNA, mecA, 
staphylococcal tuf, and spa (Lane 6), PVL-negative MSSA S. aureus  NCTC8325 strain RN6390B showing the 
bands for bacterial 16S rRNA, staphylococcal tuf, and spa (Lane 7), 100bp DNA Marker (Lane 8), PVL-negative 
MSSA S. aureus Sanger 476 harbouring SCC476 showing the DNA bands for bacterial 16S rRNA, 
staphylococcal tuf, and spa (Lane 9), PVL-negative MRSA harbouring SCCmec type 1 showing the bands for 
bacterial 16S rRNA, mecA, staphylococcal tuf, and spa (Lane 10), PVL-negative MRSA harbouring SCC mec 
type 2 showing the bands for bacterial 16S rRNA, mecA, staphylococcal tuf, and spa (Lane 11), PVL-negative 
MRSA harbouring SCCmec type 3 showing the bands for bacterial 16S rRNA, mecA, staphylococcal tuf, and spa 
(Lane 12), No Template DNA (Lane 13), PVL-positive MRSA S. aureus MW2 harbouring SCCmec type 4 
showing respectively, from top to bottom, all five markers respectively for bacterial 16S rRNA, mecA, 
staphylococcal tuf, pvl, and spa (Lane 14), PVL-negative MRSA S. aureus N315 showing the bands for bacterial 
16S rRNA, mecA, staphylococcal tuf, and spa (Lane 15), 100bp DNA Marker (Lane 16) 
1           2           3          4          5           6           7            8
9         10         11        12         13         14         15         16
200bp
200bp
100bp
100bp
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Though every effort was made to ensure the new 
assay continues to be useful, we are aware of 
the new MRSA genomes harbouring the mecC or 
mecA(LGA251) homologues of mecA. In applying 
the phenotypic tests to support the new 
pentaplex PCR assay, we did not encounter 
strains negative by mecA-PCR and 
phenotypically oxacillin-resistant, or positive by 
mecA-PCR and phenotypically oxacillin-
susceptible at 0.5 mg/L breakpoint, which is an 
attribute of the mecA(LGA251) strains [19,33]. Since 
many PCR-based MRSA assays have failed and 
it is currently perceived that MRSA PCR with 
only one set of primers for detection of methicillin 
resistance does not work because of the 
mecA(LGA251) strains [19,33], we are keeping our 
eyes on the new pentaplex PCR assay as well as 
evolving genomes in case any new strain 
renders the new assay invaluable. 
 
4. CONCLUSION  
 
Taken together, speed and specificity attributes 
suggest that the new pentaplex PCR assay is 
readily adaptable for use in routine diagnostic 
microbiology laboratories as it will enable the 
implementation of timely and properly guided 
therapy and infection control strategies. The only 
limitation of the new pentaplex PCR assay is the 
time needed to resolve the PCR amplification 
products by gel electrophoresis. To exclude the 
gel resolution time, laboratories with fat budgets 
and real-time PCR skills can always increase on 
the speed of the new pentaplex PCR assay by 
converting the same into real-time PCR since the 
detectable fragments are all tiny bits which can 
be possible with real-time PCR. However, the 
availability of real-time PCR machines capable of 
simultaneously emitting florescence signal 
through five channels makes the new assay a 
good one for laboratories to integrate into their 
workflow. While we look forward to more real-
time PCR machines with ≥5 emission channels 
and NGS and metagenomic instrumentation 
capable of sequencing longer templates, the new 
pentaplex PCR will find use in diagnostic 
microbiology especially in the developing world 
where microbiology is known for characteristic 
slim budgets. 
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